adjuvant immunotherapystage IIB/C melanomaPembrolizumabstage IIB/IIC melanomaFDA
….1%) with stage IIB and 269/3363(8.0%) with stage IIC underwent adjuvant immunotherapy. In the first year following FDA approval 426/1556(27.4%) and 3…
4articles mentioning treatments
13treatment mentions
1distinct treatments extracted
0%of mentions human-reviewed
Active filtersEntity: adjuvant immunotherapy ×
adjuvant immunotherapy
This treatment is selected. Its supporting articles are shown below.
Articles mentioning adjuvant immunotherapy
4 articles · page 1 of 1adjuvant immunotherapypenpulimabAdjuvant penpulimabvery-high risk ccRCCKEYNOTE-564 trial
…rence after nephrectomy. However, heterogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospe…
Adjuvant immunotherapytislelizumabYanbian University Hospitalhepatocellular carcinomaBCLCHCC
…ion (MWA), often resulting in early relapse and poor prognosis. Adjuvant immunotherapy may reduce this risk by eliminating residual disease and enhanc…
adjuvant immunotherapyPrecision for MedicineLow-risk stage IB/IIA cutaneous melanomaAdvarra IRB
…mains at clinically relevant risk of recurrence and death while adjuvant immunotherapy is approved only for stages IIB-IV. The previously clinically v…